# TRIUMPH-5 results: retatrutide vs tirzepatide head to head

Source: https://pepvault.app/guides/triumph-5-results

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# TRIUMPH-5 results: retatrutide vs tirzepatide head to head

Reviewed November 2026 16 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

TRIUMPH-5 puts retatrutide against tirzepatide in about 800 adults. What it tests, the numbers to beat, when it should report and how to read the result.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 16
- **Questions:** 8
- **Compounds:** 2

## The short answer

TRIUMPH-5 has not reported yet (November 20, 2026). Eli Lilly's phase 3 trial gives about 800 adults with obesity retatrutide or tirzepatide, double-blind, and measures weight change at week 80. Primary completion is November 2026, per ClinicalTrials.gov. The numbers to beat: tirzepatide 15 mg averaged 20.9% weight loss at 72 weeks in its own trial, retatrutide 12 mg 25.0% at 80 weeks.

- No result yet as of November 20, 2026; primary completion is November 2026, per ClinicalTrials.gov.
- The bar from tirzepatide's own trial: -20.9% at 72 weeks counting everyone, -22.5% had all stayed on the drug.
- Read three things when it lands: the gap in points, the estimand behind the headline, and who stopped for side effects in each arm.

Every number checked at its primary source · Nov 20, 2026 · [16 sources](https://pepvault.app/guides/triumph-5-results#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Randomised phase 2 and phase 3 trials in people (NEJM, The Lancet), Lilly's topline releases for the newest numbers (company statements), the Zepbound label and ClinicalTrials.gov records. TRIUMPH-5 itself has no results yet, and retatrutide is investigational and not approved.

## What does TRIUMPH-5 test?

TRIUMPH-5 is Eli Lilly's phase 3 trial of retatrutide against tirzepatide, the drug sold as Zepbound and Mounjaro[1](https://pepvault.app/guides/triumph-5-results#source-1). It is randomized and double-blind: each person is assigned to one drug by chance, and neither the participants nor the investigators know which one[1](https://pepvault.app/guides/triumph-5-results#source-1). The registry lists about 800 adults with obesity at 65 sites in the United States, Puerto Rico, Argentina, Germany and Poland[1](https://pepvault.app/guides/triumph-5-results#source-1). Lilly calls it the head-to-head comparison of the two drugs[10](https://pepvault.app/guides/triumph-5-results#source-10).

- **The main measure** (the primary endpoint): percent change in body weight from the start to week 80[1](https://pepvault.app/guides/triumph-5-results#source-1).
- **The other measures**, also at week 80: BMI, waist size, cholesterol, triglycerides, blood pressure, HbA1c (a three-month blood-sugar average), fasting insulin and a weight-related quality-of-life score[1](https://pepvault.app/guides/triumph-5-results#source-1).
- **Who was left out:** anyone who had taken a weight-loss drug, over-the-counter ones included, in the 90 days before screening, or whose weight had changed by more than 5 kg (11 lb) in that time[1](https://pepvault.app/guides/triumph-5-results#source-1).
- **Who is in:** Lilly describes the trial as adults with obesity with or without type 2 diabetes[10](https://pepvault.app/guides/triumph-5-results#source-10).
- **The doses:** the registry names no dose for either arm[1](https://pepvault.app/guides/triumph-5-results#source-1), so they are known only when Lilly reports.

Every comparison of the two drugs so far sets numbers from separate trials side by side. TRIUMPH-5 is the first time they meet in one study, under one set of rules.

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault's weight log keeps every weigh-in on one chart, so your own curve sits beside these trial averages when TRIUMPH-5 lands.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## How do retatrutide and tirzepatide differ?

Tirzepatide switches on two gut-hormone receptors, GIP and GLP-1, and GLP-1 is one of the body's own appetite regulators[12](https://pepvault.app/guides/triumph-5-results#source-12). Retatrutide switches on those two and a third, the glucagon receptor[11](https://pepvault.app/guides/triumph-5-results#source-11). In obese mice, the glucagon arm added extra energy burned on top of the eating-less effect of the other two[11](https://pepvault.app/guides/triumph-5-results#source-11); that extra burn is an animal result. Tirzepatide is FDA-approved, and retatrutide is not approved anywhere[10](https://pepvault.app/guides/triumph-5-results#source-10).

**Commonly reported:** appetite suppression on retatrutide that feels even stronger than on tirzepatide, stomach effects after each step-up that settle within a week or two, and a higher resting heart rate.

## What did the earlier trials show?

These are the numbers TRIUMPH-5 will be read against, each from its own trial at the top dose. All ran against placebo except SURMOUNT-5, which put tirzepatide against semaglutide. The last column says how each trial counted people, which matters more than it looks (next section).

| Trial | Drug and dose | Weeks | Average weight change | Counted |
| --- | --- | --- | --- | --- |
| SURMOUNT-1, no diabetes[2](https://pepvault.app/guides/triumph-5-results#source-2) | Tirzepatide 15 mg | 72 | -20.9% (placebo -3.1%) | Everyone randomized |
| SURMOUNT-5, no diabetes[4](https://pepvault.app/guides/triumph-5-results#source-4) | Tirzepatide 10 or 15 mg, highest tolerated | 72 | -20.2% (semaglutide -13.7%) | Not stated in the abstract |
| SURMOUNT-2, type 2 diabetes[5](https://pepvault.app/guides/triumph-5-results#source-5) | Tirzepatide 15 mg | 72 | -14.7% (placebo -3.2%) | Everyone randomized |
| TRIUMPH-1, no diabetes[7](https://pepvault.app/guides/triumph-5-results#source-7) | Retatrutide 12 mg | 80 | -25.0% (placebo -3.9%) | Everyone randomized |
| TRIUMPH-2, type 2 diabetes[9](https://pepvault.app/guides/triumph-5-results#source-9) | Retatrutide 12 mg | 80 | -20.8% (placebo -4.0%) | Had all stayed on the drug |

Earlier, in the 48-week phase 2 trial, retatrutide 12 mg averaged -24.2% against -2.1% on placebo[6](https://pepvault.app/guides/triumph-5-results#source-6). Retatrutide also has one head-to-head trial that has already read out, against semaglutide in type 2 diabetes: TRANSCEND-T2D-2, where 12 mg averaged 20.9% weight loss at 80 weeks against 9.4% on Ozempic 2 mg, had all stayed on the drug[10](https://pepvault.app/guides/triumph-5-results#source-10).

<!--promo-->

PepVault's weight log keeps every weigh-in on one chart, so your own curve sits beside these trial averages when TRIUMPH-5 lands. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-triumph-5-results-inline&mt=8)

<!--/promo-->

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Double-blind](https://pepvault.app/glossary/double-blind)
- [Primary endpoint](https://pepvault.app/glossary/primary-endpoint)
- [Confidence interval](https://pepvault.app/glossary/confidence-interval)

## Why can't the separate trials settle it?

The cross-trial gap looks large, but four things differ between the trials, and each one moves the number.

- **They count differently.** Lilly reports two numbers per trial. The treatment-regimen estimand counts everyone randomized, whether they kept taking the drug or not; the efficacy estimand estimates the result had everyone stayed on it[3](https://pepvault.app/guides/triumph-5-results#source-3) [8](https://pepvault.app/guides/triumph-5-results#source-8). The second is always the bigger one.
- **They ran for different lengths:** 80 weeks for TRIUMPH-1 and TRIUMPH-5, 72 for SURMOUNT-1[1](https://pepvault.app/guides/triumph-5-results#source-1) [2](https://pepvault.app/guides/triumph-5-results#source-2) [7](https://pepvault.app/guides/triumph-5-results#source-7). Most people who stayed on tirzepatide in SURMOUNT-1 had reached a weight plateau by week 72[16](https://pepvault.app/guides/triumph-5-results#source-16), while people with a BMI of 35 or more who stayed on retatrutide 12 mg kept losing, to 30.3% at 104 weeks[8](https://pepvault.app/guides/triumph-5-results#source-8).
- **They started at different weights:** the average BMI was 40.0 in TRIUMPH-1[8](https://pepvault.app/guides/triumph-5-results#source-8) and 38.0 in SURMOUNT-1[2](https://pepvault.app/guides/triumph-5-results#source-2).
- **Diabetes shrinks the number:** tirzepatide 15 mg averaged 14.7% with type 2 diabetes[5](https://pepvault.app/guides/triumph-5-results#source-5) against 20.9% without[2](https://pepvault.app/guides/triumph-5-results#source-2). If TRIUMPH-5 includes people with diabetes, as Lilly's description says[10](https://pepvault.app/guides/triumph-5-results#source-10), both arms may land below their obesity-only records.

| Top dose, own trial | Everyone counted | Had all stayed on the drug |
| --- | --- | --- |
| Tirzepatide 15 mg, SURMOUNT-1, 72 weeks | -20.9%[2](https://pepvault.app/guides/triumph-5-results#source-2) | -22.5%[3](https://pepvault.app/guides/triumph-5-results#source-3) |
| Retatrutide 12 mg, TRIUMPH-1, 80 weeks | -25.0%[7](https://pepvault.app/guides/triumph-5-results#source-7) | -28.3%[8](https://pepvault.app/guides/triumph-5-results#source-8) |

So the gap between separate trials is about 4 percentage points counting everyone, and about 6 counting people on the drug, with 8 extra weeks and heavier starters on retatrutide's side. TRIUMPH-5 takes all of that away: one population, one length, one way of counting.

## What would count as a good result for retatrutide?

The bar is set here, before the result, so a headline can't move it. Read four things, in this order.

- **The tirzepatide arm lands near its own record**, about 21% counting everyone in people without diabetes, as in SURMOUNT-1[2](https://pepvault.app/guides/triumph-5-results#source-2) (20.2% in SURMOUNT-5[4](https://pepvault.app/guides/triumph-5-results#source-4)). That shows the trial was a fair fight; a lower number is expected if many participants have diabetes[5](https://pepvault.app/guides/triumph-5-results#source-5).
- **The gap between the arms**, in percentage points at week 80. For scale, tirzepatide beat semaglutide by 6.5 points at 72 weeks in SURMOUNT-5 (20.2% against 13.7%)[4](https://pepvault.app/guides/triumph-5-results#source-4). A gap of 6 points or more would be a clear win on that scale; about 4 points would confirm what the separate trials suggest; 2 or 3 points would still favour retatrutide, but narrowly.
- **The estimand behind the headline.** Lilly's TRIUMPH releases lead with the efficacy estimand[8](https://pepvault.app/guides/triumph-5-results#source-8) [9](https://pepvault.app/guides/triumph-5-results#source-9), so set a headline retatrutide number against tirzepatide's 22.5%[3](https://pepvault.app/guides/triumph-5-results#source-3), not its 20.9%.
- **Who stopped for side effects, in each arm.** In their own trials, 11.3% stopped on retatrutide 12 mg against 4.9% on placebo[8](https://pepvault.app/guides/triumph-5-results#source-8), and 6.2% on tirzepatide 15 mg against 2.6%[2](https://pepvault.app/guides/triumph-5-results#source-2). A weight win with twice the drop-out is a different choice from a win at equal tolerability.

One side effect is specific to watch. Dysesthesia, skin that feels unusual or uncomfortable to the touch, came in 12.5% on retatrutide 12 mg against 0.9% on placebo in TRIUMPH-1, and Lilly says the cases were generally mild to moderate and most resolved during treatment[8](https://pepvault.app/guides/triumph-5-results#source-8). Zepbound's label, pooling its two main obesity trials, lists it in 0.4% on 15 mg against 0.1% on placebo[12](https://pepvault.app/guides/triumph-5-results#source-12). TRIUMPH-5 will show both rates in the same trial.

## When will TRIUMPH-5 report?

Primary completion, the date the last participant reaches the week-80 measure, is November 2026, an estimate per ClinicalTrials.gov; the whole study is estimated to end in December 2026, and the record was last updated in July 2026[1](https://pepvault.app/guides/triumph-5-results#source-1). Lilly has given no date for the results: its October 28 release calls the trial ongoing[10](https://pepvault.app/guides/triumph-5-results#source-10).

Lilly's last three retatrutide readouts set a pattern: the topline press release came 6 to 15 weeks after primary completion.

| Trial | Primary completion (ClinicalTrials.gov) | Topline release | Gap |
| --- | --- | --- | --- |
| TRIUMPH-1[13](https://pepvault.app/guides/triumph-5-results#source-13) | April 6, 2026 | May 21, 2026[8](https://pepvault.app/guides/triumph-5-results#source-8) | 6 weeks |
| TRANSCEND-T2D-2[15](https://pepvault.app/guides/triumph-5-results#source-15) | August 27, 2026 | October 28, 2026[10](https://pepvault.app/guides/triumph-5-results#source-10) | 9 weeks |
| TRIUMPH-2[14](https://pepvault.app/guides/triumph-5-results#source-14) | June 16, 2026 | September 29, 2026[9](https://pepvault.app/guides/triumph-5-results#source-9) | 15 weeks |

On that pattern, a November primary completion puts the TRIUMPH-5 topline between mid-December 2026 and mid-March 2027. That is our arithmetic from the dates above, not a date from Lilly. Lilly set TRIUMPH-1's fuller results for the American Diabetes Association's Scientific Sessions[8](https://pepvault.app/guides/triumph-5-results#source-8), and the paper came out in the New England Journal of Medicine on September 29[7](https://pepvault.app/guides/triumph-5-results#source-7). Lilly plans to file retatrutide with the FDA in the first quarter of 2027[9](https://pepvault.app/guides/triumph-5-results#source-9).

## Has TRIUMPH-5 reported yet?

Not as of November 20, 2026. ClinicalTrials.gov shows no posted results[1](https://pepvault.app/guides/triumph-5-results#source-1), and Lilly's releases name the trial only as ongoing[10](https://pepvault.app/guides/triumph-5-results#source-10). This page is updated the day the topline lands, with the numbers, the source and the time of the update.

The result compares two drugs in a trial. It sets no dose for anyone, and retatrutide stays unapproved until the FDA rules on it[10](https://pepvault.app/guides/triumph-5-results#source-10). For someone on tirzepatide today, the result changes nothing about the current prescription; a change of drug is a conversation with the prescriber.

<!--promo-->

PepVault logs each dose with its date, so a talk with your prescriber starts from your own record rather than memory. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-triumph-5-results-inline&mt=8)

<!--/promo-->

## How do you read the TRIUMPH-5 result when it lands?

1. Open Lilly's release and check the trial name and number: TRIUMPH-5, NCT06662383.
2. Find the primary endpoint: percent weight change at week 80, one number per arm.
3. Check which estimand that number uses; the endnotes of Lilly's releases say.
4. Subtract the tirzepatide number from the retatrutide number. That gap, in percentage points, is the result: set it against the 4-point (everyone counted) or 6-point (on the drug) gap between the separate trials.
5. Find the doses each arm reached, and whether people with type 2 diabetes were included.
6. Find the share who stopped for side effects in each arm, and the dysesthesia rate.
7. Wait for the journal paper for what a release leaves out: the full side-effect tables and the confidence intervals around each number.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. TRIUMPH-5: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity. ClinicalTrials.gov NCT06662383. Eli Lilly and Company. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06662383)
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. [PubMed 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)
3. Eli Lilly and Company. Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss. Press release, June 4, 2022. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-surmount-1-results-published-in-the-new-england-journal-of-medicine-show-tirzepatide-achieved-between-16-0-and-22-5-weight-loss-in-adults-with-obesity-or-overweight-301561327.html)
4. Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025. [PubMed 40353578](https://pubmed.ncbi.nlm.nih.gov/40353578/)
5. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023. [PubMed 37385275](https://pubmed.ncbi.nlm.nih.gov/37385275/)
6. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. [PubMed 37366315](https://pubmed.ncbi.nlm.nih.gov/37366315/)
7. Jastreboff AM et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med. 2026. [PubMed 42814954](https://pubmed.ncbi.nlm.nih.gov/42814954/)
8. Eli Lilly and Company. Lilly's triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Press release, May 21, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html)
9. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction (TRIUMPH-2). Press release, September 29, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-substantial-weight-loss-and-a1c-reduction-underscoring-its-potential-promise-for-people-with-obesity-and-type-2-diabetes-302891798.html)
10. Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (TRANSCEND-T2D-2). Press release, October 28, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html)
11. Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022. [PubMed 35985340](https://pubmed.ncbi.nlm.nih.gov/35985340/)
12. Zepbound (tirzepatide) injection, prescribing information. DailyMed, revised August 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
13. TRIUMPH-1. ClinicalTrials.gov NCT05929066. Eli Lilly and Company. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05929066)
14. TRIUMPH-2. ClinicalTrials.gov NCT05929079. Eli Lilly and Company. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05929079)
15. TRANSCEND-T2D-2: Retatrutide compared with semaglutide in type 2 diabetes. ClinicalTrials.gov NCT06260722. Eli Lilly and Company. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06260722)
16. Horn DB et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025. [PubMed 39800653](https://pubmed.ncbi.nlm.nih.gov/39800653/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)

CagriSema is not FDA approved yet (Nov 20, 2026); Novo expects a decision in Q4 2026. The dose it filed, the warnings to expect and five trials' numbers.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Retatrutide Studied range: 1–12 mg](https://pepvault.app/peptides/retatrutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)

## Related guides

- Guide · GLP-1s

  ### [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)

  No trial has tested a switch from tirzepatide to retatrutide. What each drug's trials and the Zepbound label say, how the two differ, and what is still unknown.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)

  Retatrutide dosage in trials: a 2 mg weekly start, a step up every four weeks to 4, 9 or 12 mg in phase 3, what phase 2 tested, and why no label exists.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)

  What to expect on retatrutide week by week: the trial dose steps, when appetite drops, weight loss at weeks 24, 48 and 80, and how side effects settle.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)

  Retatrutide not working? What the trials show: the climb to the top dose, how many people barely responded, why diabetes slows loss, and what a plateau is.

  Read the guide
- Guide · GLP-1s

  ### [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)

  What to expect on tirzepatide week by week: the label's dose steps, when appetite and nausea change, weight loss from week 20 to year 3, and the plateau.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Double-blind](https://pepvault.app/glossary/double-blind)
- [Primary endpoint](https://pepvault.app/glossary/primary-endpoint)
- [Confidence interval](https://pepvault.app/glossary/confidence-interval)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
